Fed. Circ. Trims Daiichi Costs Award In Levaquin Suit
A federal appeals court has nixed some of the costs awarded to Daiichi Pharmaceutical Co. Ltd. after it won a patent dispute over its antibiotic drug Levaquin against Mylan Laboratories Inc.,...To view the full article, register now.
Already a subscriber? Click here to view full article